Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Faron Pharmaceuticals Oy ( (GB:FARN) ).
Faron Pharmaceuticals Ltd has announced the grant of 180,000 options over ordinary shares under its Share Option Plan 2019. This move allows option holders to subscribe to new ordinary shares, representing 0.16% of the company’s fully diluted share capital, potentially enhancing stakeholder engagement and aligning management interests with company growth.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to combat cancer. The company aims to extend the benefits of immunotherapy to a broader population by discovering innovative methods to control and utilize the immune system’s power.
For an in-depth examination of FARN stock, go to TipRanks’ Overview page.